Clinical Trial Results:
Estudio VITAL- Estudio del activador del receptor de la vitamina D selectivo (Paricalcitol) para la reducción de la albúmina: Estudio multicéntrico de fase II, prospectivo aleatorizado, a doble ciego y controlado mediante placebo, para evaluar la seguridad y eficacia de las cápsulas de paricalcitol en la reducción de la albuminuria en pacientes con diabetes de tipo 2 que presentan nefropatía y que están siendo tratados actualmente con inhibidores del sistema renina-angiotensina.
VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors.
Summary
|
|
EudraCT number |
2006-001363-31 |
Trial protocol |
ES DE PT GR IT NL |
Global completion date |
09 Jun 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Jun 2016
|
First version publication date |
03 Jun 2016
|
Other versions |
|
Summary report(s) |
M05-741 Study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.